Dilation of renal artery stenosis after administration of losartan

Hypertension Research

Volumn 30, Issue 10, 2007, Pages 999-1002

  Tanemoto, Masayuki ^a   Takase, Kei ^a   Yamada, Takayuki ^a   Satoh, Akihiro ^a   Abe, Takaaki ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Angioplasty; Angiotensin; Fibromuscular dysplasia; Hypertension; Renal artery stenosis

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; ARTERIAL PRESSURE; ARTERY DILATATION; ARTICLE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; FEMALE; FIBROMUSCULAR DYSPLASIA; FOLLOW UP; HUMAN; KIDNEY ARTERIOGRAPHY; KIDNEY ARTERY STENOSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMA RENIN ACTIVITY; RENOVASCULAR HYPERTENSION; REPEAT PROCEDURE; RESTENOSIS;

ADULT; ANGIOPLASTY, BALLOON; ANTIHYPERTENSIVE AGENTS; FEMALE; FIBROMUSCULAR DYSPLASIA; HUMANS; HYPERTENSION, RENOVASCULAR; LOSARTAN; RENAL ARTERY OBSTRUCTION; TREATMENT FAILURE;

EID: 36248992790     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.999     Document Type: Article

References (21)

1. Bokhari SW, Faxon DP: Current advances in the diagnosis and treatment of renal artery stenosis. Rev Cardiovasc Med 2004; 5: 204-215.
2. Tegtmeyer CJ, Selby JB, Hartwell GD, Ayers C, Tegtmeyer V: Results and complications of angioplasty in fibromuscular disease. Circulation 1991; 83: I155-I161.
3. White CJ, Ramee SR, Collins TJ, Jenkins JS, Escobar A, Shaw D: Renal artery stent placement: utility in lesions difficult to treat with balloon angioplasty. J Am Coll Cardiol 1997; 30: 1445-1450.
4. Tanemoto M, Abe T, Chaki T, Satoh F, Ishibashi T, Ito S: Cutting balloon angioplasty of resistant renal artery stenosis caused by fibromuscular dysplasia. J Vasc Surg 2005; 41: 898-901.
5. Perkovic V, Thomson KR, Mitchell PJ, et al: Treatment of renovascular disease with percutaneous stent insertion: long-term outcomes. Australas Radiol 2001; 45: 438-443.
6. Barath P, Fishbein MC, Vari S, Forrester JS: Cutting balloon: a novel approach to percutaneous angioplasty. Am J Cardiol 1991; 68: 1249-1252.
7. Kyoraku Y, Kato J, Nishi Y, et al: Autotransplantation and stent implantation for bilateral renal artery fibromuscular dysplasia. Hypertens Res 1999; 22: 141-143.
8. Stanley JS: Renal artery fibrodysplasia. in Novick AC (ed): Renal Vascular Disease. London, WB Saunders Company Ltd, 1996, pp 21-33.
9. Wilson DP, Saward L, Zahradka P, Cheung PK: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 1999; 42: 761-772.
10. Wilensky RL: Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Cardiovasc Drugs Ther 2003; 17: 63-73.
11. Nemcek AA Sr, Holmburg CE: Reversible renal fibromuscular dysplasia. AJR Am J Roentgenol 1986; 147: 737-738.
12. Osterrieder W, Muller RK, Powell JS, Clozel JP, Hefti F, Baumgartner HR: Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 1991; 18: II60-II64.
13. Kramer C, Sunkomat J, Witte J, et al: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776.
14. Fujikawa K, Hasebe N, Kikuchi K: Cost-effectiveness analysis of hypertension treatment: controlled release nifedipipe and candesartan low-dose combination therapy in patients with essential hypertension - the Nifedipine and Candesartan Combination (NICE-Combi) Study. Hypertens Res 2005; 28: 585-591.
15. Harrap SB, Van der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16: 603-614.
16. Nakaya H, Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659-666.
17. Habashi JP, Judge DP, Holm TM, et al: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121.
18. Hackam DG, Thiruchelvam D, Redelmeier DA: Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368: 659-665.
19. Hara K, Kobayashi N, Nakano S, Mori Y, Tsubokou Y, Matsuoka H: Effects of TCV-116 on endothelin-1 and PDGF A - chain expression in angiotensin II-induced hypertensive rats. Hypertens Res 2001; 24: 55-64.
20. Rakugi H, Wang DS, Dzau VJ, Pratt RE: Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994; 90: 449-455.
21. Navar LG, Harrison-Bernard LM: Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res 2000; 23: 291-301.